A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)(COMPLETED)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infection; Pneumonia
Intervention: MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days (Drug); Comparator: amikacin / Duration of Treatment: 3 Days (Drug); Comparator: tazocin / Duration of Treatment: 3 Days (Drug); Comparator: vancomycin / Duration of Treatment: 3 Days (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Sharp & Dohme Corp. Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.
Summary
The primary objective of this study is a comparison between MK0787B and standard therapy.
Clinical Details
Official title: A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Greater than 18 years of age
- Patient is diagnosed with nosocomial pneumonia
Exclusion Criteria:
- Immunological deficient patients
- Pregnant women and nursing mothers
- A fungus is identified before the study enrollment
- Received vancomycin or imipenem for more than 5 days before icu admission
Locations and Contacts
Additional Information
Starting date: November 2006
Last updated: September 26, 2014
|
